Ruiz Villaverde, RicardoDomínguez Cruz, JavierNavarro Triviño, Francisco J.Galán Gutiérrez, ManuelArmario Hita, José CarlosPereyra-Rodríguez, José-Juan2023-06-222023-06-222022Ruiz Villaverde, R., Domínguez Cruz, J., Navarro Triviño, F.J., Galán Gutiérrez, M., Armario Hita, J.C. y Pereyra-Rodríguez, J. (2022). Atopic Dermatitis: Background, Objectives and Future Perspectives (Superresponders). Life, 12 (8), 1192. https://doi.org/10.3390/life12081192.2075-1729https://hdl.handle.net/11441/147422In this Special Issue entitled Atopic Dermatitis: New Perspectives, we have tried to collect research of special interest related mainly to the incorporation of pathophysiological aspects and therapeutic novelties in this regard. Pereyra et al. [1] carry out a systematic review and network meta-analysis (NMA) in which they carry out a short-term evaluation of the short-term efficacy and safety of biological molecules and small molecules that have recently been incorporated into our therapeutic arsenal. Upadacitinib and Abrocitinib are the drugs with the highest efficacy, both in monotherapy and in association with TCS. However, they were also those associated with the highest risk of adverse effects, showing monoclonal antibodies’ better safety profile.application/pdf4 p.engAtribución 4.0 Internacionalhttp://creativecommons.org/licenses/by/4.0/Atopic dermatitisinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccesshttps://doi.org/10.3390/life12081192